List view / Grid view
Advances in informatics have afforded researchers the ability to extrapolate petabytes of human genomics data and translate it into biologically relevant information. However, further translating this information into knowledge can prove challenging. Slavé Petrovski, Vice President and Head of Genome Analytics and Bioinformatics for AstraZeneca’s Centre for Genomics Research, spoke…
The future of drug discovery lies in an automated world where the workflows for biological assays, chemical synthesis and data analysis are connected by flexible, mobile and modular hardware, integrated with software solutions that will interface with scientists for increased efficiency and productivity (the realisation of Industry 4.0). This article…
Researchers will create the first human heart-in-a-jar to study heart failure, identify new therapeutic targets and test novel treatments.
On 5-6 November, ACC Liverpool hosted the ELRIG Drug Discovery event, which allowed R&D professionals to come together and discuss the latest industry developments.
AI has applications in many areas of research, including genomics. Slavé Petrovski of AstraZeneca reveals how AI is used in the study of the human genome and how it may evolve in the future.
Claus Bendtsen at AstraZeneca reveals how AI can be used to improve our understanding of disease, to help identify the causes of conditions and aid in drug discovery.
A new AI project marks the first time 10 pharmaceutical companies have agreed to share data to aid drug discovery.
A new study has shown that an experimental drug known as AZ32 significantly extends the survival of glioblastoma multiforme, the most common and deadly form of brain cancer...
Advances in genomics and structural biology are providing drug discovery scientists with more biological targets to prosecute, and greater information about each one.
Signs collaboration agreement with AstraZeneca to offer state-of-the-art technology to clients.
A team of researchers from the University of Liverpool and AstraZeneca has made an important contribution to our understanding of cancer cell regulation, holding promise for improved future cancer treatment.
A new race is well underway involving big pharma and big data companies to see who can most effectively mine the new massive data using artificial intelligence (AI). The aim: reducing costs by using targeted in silico analysis, reducing in vitro and in vivo screening, and reviewing huge quantities of…
Dr Goodwin is the latest top-level scientist to join DTR's advisory board
11 October 2017 | By
Principal Scientist, Drug Safety and Metabolism at AstraZeneca
Mass spectrometry imaging allows direct measurement of the molecular composition of a sample. It can be used to image the spatial distribution of exogenous drugs and endogenous metabolites simultaneously over the surface of tissue sections or small biopsy, allowing new insights into both compound efficacy and safety during drug discovery.
